Nationwide Children's Hospital is constructing a $100 million gene therapy manufacturing center in Columbus, Ohio. The 185,000-sf facility will enable Andelyn Biosciences, a for-profit subsidiary of Nationwide Children's, to supply pharmaceutical and biotechnology companies with genetic material for use in research and clinical trials. Located in The Ohio State University's Innovation District, the leased structure will feature advanced cGMP environments for commercial-scale manufacturing. Ground was broken on the center in November of 2020 with operations commencing in 2022.
The facility will augment Nationwide Children's existing production capacity at the Abigail Wexner Research Institute's biologics manufacturing hub. The project represents the first phase of development at the site, which will accommodate a subsequent expansion of similar size to create a dynamic nexus for gene therapy excellence.